Paroxysmal Nocturnal Hemoglobinuria pipeline Research Monitor, 2020- Drugs, Companies, Clinical Trials, R&D pipeline updates, status and outlook

July 2020 | 106 pages | ID: P8D0E0FDE5E3EN
VPAResearch

Abstracts

2020 Paroxysmal Nocturnal Hemoglobinuria PIPELINE HIGHLIGHTS
Paroxysmal Nocturnal Hemoglobinuria is one of the widely researched conditions during 2020 with 18 companies actively focusing on realizing pipeline’s potential. Development of Paroxysmal Nocturnal Hemoglobinuria medicines is identified as integral to the strategy of the majority of companies operating in the industry.
Global Paroxysmal Nocturnal Hemoglobinuria market presents promising new product pipeline with NME Projects, pivotal trials, and rapidly phase-advancing therapeutic candidates. Increasing number of companies are assessing the feasibility of developing treatment options for Paroxysmal Nocturnal Hemoglobinuria.

Good progress is anticipated during 2020 and 2021 with Paroxysmal Nocturnal Hemoglobinuria pipeline molecules advancing from pre-clinical investigation to completion of advanced Phase clinical trials. Paroxysmal Nocturnal Hemoglobinuria pipeline continues to expand and progress with novel mechanisms and diverse routes of administration being tested by companies.
Paroxysmal Nocturnal Hemoglobinuria DRUG DEVELOPMENT PIPELINE OVERVIEW
The “Paroxysmal Nocturnal Hemoglobinuria pipeline Research Monitor, 2020” report is an analytical research study on the progress achieved by pipeline companies during the year along with its historical development, current status, and outlook.
This Paroxysmal Nocturnal Hemoglobinuria pipeline review explores high-potential early to late-stage pipeline projects with a continued focus on new insights, accelerated processes, and pipeline progression.

The competitive intelligence report on Paroxysmal Nocturnal Hemoglobinuria presents detailed insights into therapeutic drug pipeline development, industry news, deals, and analysis across the length and breadth of the Paroxysmal Nocturnal Hemoglobinuria pipeline. Information on R&D pipeline updates, results of key clinical trials are also included in the report.
Paroxysmal Nocturnal Hemoglobinuria DRUG PROFILES
Paroxysmal Nocturnal Hemoglobinuria development pipeline including projects in early- and late-stage development are detailed in the report. Details of clinical trial data and submissions to regulatory authorities are also provided. For the drug candidates included in the report, the following information is provided-

• Current Status of Development including phase advancements, regulatory approvals of phases, acquisitions, licensing and technology transfers, product launches in various markets, and others.
• Phase of development
• Mechanism of Action
• Route of Administration
• Companies involved including originator, licensing companies, developer, investors, and others
• New molecular entity details
• Orphan drug designation and other special status provided by regulators

Paroxysmal Nocturnal Hemoglobinuria COMPANY PROFILES

Both small size and large size pharmaceutical companies are investing their resources in Paroxysmal Nocturnal Hemoglobinuria drug development operations. Further, financial institutions are extending support to small pharmaceutical companies, universities, and other researchers for the development of treatment of Paroxysmal Nocturnal Hemoglobinuria. Partnerships and acquisitions are also increasingly observed in the pipeline.

This research report presents an analysis of 18 Paroxysmal Nocturnal Hemoglobinuria companies including company overview, key snapshot, contact information, and their strategies on accelerating Paroxysmal Nocturnal Hemoglobinuria pipeline development. Mid-stage and early portfolios of these companies are analyzed in detail in the report.

Companies analyzed in the report include- Aevitas Therapeutics Inc, Akari Therapeutics Plc, Alexion Pharmaceuticals Inc, Alnylam Pharmaceuticals Inc, Amgen Inc, Amyndas Pharmaceuticals LLC, Apellis Pharmaceuticals Inc, Attune Pharmaceuticals, Biocad, BioCryst Pharmaceuticals Inc, Chugai Pharmaceutical Co Ltd, ISU ABXIS Co Ltd, Novartis AG, NovelMed Therapeutics Inc, Omeros Corp, Ra Pharmaceuticals Inc, Regeneron Pharmaceuticals Inc, Samsung Bioepis Co Ltd

REASONS TO BUY

• The current market conditions are forcing companies and investors worldwide to prioritize their investments and accelerate pipeline candidates only through careful quantitative assessment.
• This research work assists decision makers in pharmaceutical companies towards successful pipeline development through critically evaluated pipeline data
• Buyers can identify most promising drug candidates for treatment of Paroxysmal Nocturnal Hemoglobinuria
• It allows users to strengthen their pipeline through acquisitions, licensing and collaborations
• Users can estimate possible delays in the delivery of pipeline or launch of new products
• Stay ahead of competition through understanding their pipeline progression, strategies and outlook
• The report details all the pipeline candidates under investigation in various stages of development from Phase I through to Phase III to enable business development managers to understand the impact of new launches.
• Optimize your licensing and technology transfer strategies through identification of prospect partners

Contents

1. INTRODUCTION TO PAROXYSMAL NOCTURNAL HEMOGLOBINURIA

1.1 Paroxysmal Nocturnal Hemoglobinuria- Disease overview
1.2 Paroxysmal Nocturnal Hemoglobinuria- Market Size
1.3 Paroxysmal Nocturnal Hemoglobinuria- Companies Involved

2. PAROXYSMAL NOCTURNAL HEMOGLOBINURIA PIPELINE SNAPSHOT- 2020

2.1 Paroxysmal Nocturnal Hemoglobinuria Pipeline by Phase
2.2 Paroxysmal Nocturnal Hemoglobinuria Pipeline by Mechanism of Action
2.3 Paroxysmal Nocturnal Hemoglobinuria Pipeline by Route of Administration
2.4 Paroxysmal Nocturnal Hemoglobinuria Pipeline- New Molecular Entities
2.5 Paroxysmal Nocturnal Hemoglobinuria Pipeline- Orphan Drug Designation/ Special Designation

3. PAROXYSMAL NOCTURNAL HEMOGLOBINURIA DRUG PROFILES

3.1 Current Status
3.2 Paroxysmal Nocturnal Hemoglobinuria Drug Snapshot
3.3 Paroxysmal Nocturnal Hemoglobinuria Therapeutic Candidates- Originator/Licensor
3.4 Route of Administration
3.5 Mechanism of Action
3.6 NME
4.1 Aevitas Therapeutics Inc Paroxysmal Nocturnal Hemoglobinuria Pipeline Insights and Clinical Trials
4.2 Akari Therapeutics Plc Paroxysmal Nocturnal Hemoglobinuria Pipeline Insights and Clinical Trials
4.3 Alexion Pharmaceuticals Inc Paroxysmal Nocturnal Hemoglobinuria Pipeline Insights and Clinical Trials
4.4 Alnylam Pharmaceuticals Inc Paroxysmal Nocturnal Hemoglobinuria Pipeline Insights and Clinical Trials
4.5 Amgen Inc Paroxysmal Nocturnal Hemoglobinuria Pipeline Insights and Clinical Trials
4.6 Amyndas Pharmaceuticals LLC Paroxysmal Nocturnal Hemoglobinuria Pipeline Insights and Clinical Trials
4.7 Apellis Pharmaceuticals Inc Paroxysmal Nocturnal Hemoglobinuria Pipeline Insights and Clinical Trials
4.8 Attune Pharmaceuticals Paroxysmal Nocturnal Hemoglobinuria Pipeline Insights and Clinical Trials
4.9 Biocad Paroxysmal Nocturnal Hemoglobinuria Pipeline Insights and Clinical Trials
4.10 BioCryst Pharmaceuticals Inc Paroxysmal Nocturnal Hemoglobinuria Pipeline Insights and Clinical Trials
4.11 Chugai Pharmaceutical Co Ltd Paroxysmal Nocturnal Hemoglobinuria Pipeline Insights and Clinical Trials
4.12 ISU ABXIS Co Ltd Paroxysmal Nocturnal Hemoglobinuria Pipeline Insights and Clinical Trials
4.13 Novartis AG Paroxysmal Nocturnal Hemoglobinuria Pipeline Insights and Clinical Trials
4.14 NovelMed Therapeutics Inc Paroxysmal Nocturnal Hemoglobinuria Pipeline Insights and Clinical Trials
4.15 Omeros Corp Paroxysmal Nocturnal Hemoglobinuria Pipeline Insights and Clinical Trials
4.16 Ra Pharmaceuticals Inc Paroxysmal Nocturnal Hemoglobinuria Pipeline Insights and Clinical Trials
4.17 Regeneron Pharmaceuticals Inc Paroxysmal Nocturnal Hemoglobinuria Pipeline Insights and Clinical Trials
4.18 Samsung Bioepis Co Ltd Paroxysmal Nocturnal Hemoglobinuria Pipeline Insights and Clinical Trials

5. PAROXYSMAL NOCTURNAL HEMOGLOBINURIA MARKET NEWS AND UPDATES

6. APPENDIX

6.1 Sources and Methodology
6.2 Contact Information